Wei Wei, MD, PhD
Assistant Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Contact Info
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Biography
Wei Wei is an Assistant Professor in the Department of Biostatistics at the Yale School of Public Health. He received his Ph.D. in Biostatistics from the Medical University of South Carolina and joined the Department of Biostatistics at YSPH in 2017 as an associate research scientist. Dr. Wei's research area focuses on development of early phase clinical trial designs, with particular interest in cancer targeted and immunotherapeutic agents. In addition to his research in cancer clinical trials, Wei’s research expertise also includes statistical genomics, biomarker discovery and neurophysiology.
Appointments
Medical Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Yale Cancer Center
Education & Training
- PhD
- Medical University of South Carolina, Biostatistics (2016)
- MD
- Norman Bethune College of Medicine Jilin University (2006)
Research
Overview
Public Health Interests
Biomarkers; Clinical Trials; Cancer; Global Health
ORCID
0000-0003-1263-5620
Research at a Glance
Yale Co-Authors
Frequent collaborators of Wei Wei's published research.
Daniel Zelterman, PhD
Denise Esserman, PhD
Harriet Kluger, MD
Kurt Schalper, MD, PhD
Michael Cecchini, MD
Michael Kane, PhD, MA, MS
Publications
2024
Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials
Wei W, Zhang Y, Roychoudhury S, Initiative T. Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials. Statistics In Medicine 2024, 43: 3815-3829. PMID: 38924575, DOI: 10.1002/sim.10158.Peer-Reviewed Original ResearchAltmetricA Bayesian platform trial design with hybrid control based on multisource exchangeability modelling
Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics In Medicine 2024, 43: 2439-2451. PMID: 38594809, PMCID: PMC11325877, DOI: 10.1002/sim.10077.Peer-Reviewed Original ResearchCitationsrBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors
Wang X, Wei W. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors. Contemporary Clinical Trials 2024, 140: 107505. PMID: 38521384, DOI: 10.1016/j.cct.2024.107505.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsPhase II basket trialRobust Bayesian modelBasket trial designBiomarker-defined subgroupsMixture priorsBinary endpointsModel averaging methodPosterior distributionBayesian modelBasket trialsSimulation studyEra of targeted therapyDevelopment of targeted agentsPriorsAverage methodGenomic alterationsPatient populationNovel treatmentAntitumor activityPosterior weightsEarly phase oncology trialsStatistical powerOncology trialsTrial designTrials
2023
A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1
Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Gonzalez-Cao M, Arance A, Wei W, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical Cancer Research 2023, 30: 74-81. PMID: 37535056, PMCID: PMC10767304, DOI: 10.1158/1078-0432.ccr-23-0475.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObjective response ratePhase II trialAdverse eventsPartial responseDisease progressionII trialGrade 3 adverse eventsAnti PD-1CD40 agonist antibodyElevated liver functionTreatment-related SAEsCommon adverse eventsActivation of CD40Subset of patientsFavorable safety profileAntigen presenting cellsStable diseaseMedian durationAdvanced melanomaAdditional patientsLiver functionSafety profileMetastatic melanomaPreclinical dataPresenting cellsQuantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersNCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
Cecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications 2023, 3: 1113-1117. PMID: 37377610, PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDose-limiting toxicityHomologous recombination deficiencyPARP inhibitorsStable diseaseWeekly irinotecanObjective responseDay 1Day 3Solid tumorsPhase I dose-escalation studyTwice daily days 1I dose-escalation studyPhase I clinical trialDaily days 1Dose level 1Doses of veliparibGrade 3 neutropeniaMultiple-dose schedulesProgression-free survivalAdvanced solid tumorsDose-escalation studyEvaluable patientsNonoverlapping toxicitiesDose scheduleSystemic treatmentPeripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.
Merkin R, Schoenfeld D, Djureinovic D, Austin M, Wang M, Qu R, Zhang L, Mann J, Wei W, Sun L, Aizenbud L, Destina J, Kluger H. Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration. Journal Of Clinical Oncology 2023, 41: e14694-e14694. DOI: 10.1200/jco.2023.41.16_suppl.e14694.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsSevere immune-related adverse eventsPeripheral blood immune cellsBlood immune cellsSteroid therapyDose levelsSteroid taperAdverse eventsIL-6Immune cellsImmune checkpoint inhibitor-related adverse eventsSeverity of irAEsMultiple immune-related adverse eventsAnti-PD-1 therapyT effector memory cellsPeripheral blood mononuclear cellsYale Cancer CenterSerum cytokine concentrationsEffector memory cellsPathogenic T cellsBlood mononuclear cellsConcentrations of TNFαBiomarkers of responseT cell subtypes
2022
Regression methods for the appearances of extremes in climate data
Yu C, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. Regression methods for the appearances of extremes in climate data. Environmetrics 2022, 33 DOI: 10.1002/env.2764.Peer-Reviewed Original ResearchCitationsAltmetricConcepts
News
News
Get In Touch
Contacts
Email